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Abstract
The Vpr protein of human immunodeficiency virus type 1 (HIV-1) contributes to viral replication in non-dividing cells,
specifically those of the myeloid lineage. However, the effects of Vpr in enhancing HIV-1 infection in dendritic cells have not
been extensively investigated. Here, we evaluated the role of Vpr during infection of highly permissive peripheral blood
mononuclear cells (PBMCs) and CD4
+ T-cells and compared it to that of monocyte-derived dendritic cells (MDDCs), which
are less susceptible to HIV-1 infection. Infections of dividing PBMCs and non-dividing MDDCs were carried out with single-
cycle and replication-competent HIV-1 encoding intact Vpr or Vpr-defective mutants. In contrast to previous findings, we
observed that single-cycle HIV-1 infection of both PBMCs and MDDCs was significantly enhanced in the presence of Vpr
when the viral stocks were carefully characterized and titrated. HIV-1 DNA quantification revealed that Vpr only enhanced
the reverse transcription and nuclear import processes in single-cycle HIV-1 infected MDDCs, but not in CD4
+ T-cells.
However, a significant enhancement in HIV-1 gag mRNA expression was observed in both CD4
+ T-cells and MDDCs in the
presence of Vpr. Furthermore, Vpr complementation into HIV-1 virions did not affect single-cycle viral infection of MDDCs,
suggesting that newly synthesized Vpr plays a significant role to facilitate single-cycle HIV-1 infection. Over the course of a
spreading infection, Vpr significantly enhanced replication-competent HIV-1 infection in MDDCs, while it modestly
promoted viral infection in activated PBMCs. Quantification of viral DNA in replication-competent HIV-1 infected PBMCs and
MDDCs revealed similar levels of reverse transcription products, but increased nuclear import in the presence of Vpr
independent of the cell types. Taken together, our results suggest that Vpr has differential effects on single-cycle and
spreading HIV-1 infections, which are dependent on the permissiveness of the target cell.
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Introduction
Among the four accessory proteins of HIV-1, the viral protein
R (Vpr) has been widely investigated due to its efficient
incorporation in the virion particle, its ability to alter the cell
cycle, and its cytopathic nature (reviewed in [1,2,3]). Vpr is a
small, 96-amino acid protein that is expressed in the infected cell
from the provirus as a late viral gene product from a singly
spliced mRNA [4], and is efficiently incorporated into the viral
particle through its interaction with the C-terminal p6 region of
the Gag precursor [5]. Due to its ability to interact with
numerous cellular proteins [6,7], several functions have been
ascribed to Vpr. These include the induction of cell cycle arrest
in the G2 phase [8], long-terminal-repeat (LTR)-transactivation
[9,10,11,12], induction of apoptosis [13], enhancement of the
fidelity of reverse transcription [14], and impairment of host
immune function for HIV-1 evasion [15,16]. For instance, the
Vpr-binding protein (VprBP), also called DDB1 (damaged DNA
binding protein 1)- and Cullin-4 (Cul4)-associated factor 1
(DCAF1), is important for cell cycle regulation [7]. A current
working model proposes that Vpr might be capable of targeting
an unknown cell cycle regulatory factor for proteasomal
degradation via the recruitment of the DDB1/DCAF1/Cul4A
complex, which enables Vpr-mediated cell cycle arrest in the G2
phase of dividing cells [17,18,19,20]. However, the role of
DCAF1 in HIV-1 infection remains to be examined.
Another key function of Vpr is its requirement for HIV-1
infection in non-dividing cells such as macrophages in vitro
[21,22,23,24,25]. It does so mainly by playing a chaperone-like
role for importing the pre-integration complex containing the
reverse transcribed viral DNA into the nucleus of the non-dividing
cell, a function that is thought to be redundant in proliferating cells
such as activated CD4
+ T-cells where dissolution of the nuclear
envelope occurs to facilitate integration of the viral genome [26].
Several reports suggest that other viral components such as capsid
(CA) [27,28], integrase (IN) [29], and the central DNA flap, which
contains the polypurine tract-central termination sequence (cPPT-
CTS) [30,31], are required for nuclear import of viral DNA,
especially in non-dividing cells. However, discrepancies exist with
regard to the involvement of some of these viral factors in nuclear
import [32,33]. Recently, Rivie `re et al. performed a comprehen-
sive analysis to identify which viral component among IN, Vpr,
MA, and the cPPT-CTS was vital for the nuclear import of HIV-1
DNA in dividing and non-dividing cell types [30]. Using a
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May  3vesicular stomatitis glycoprotein (VSV-G) pseudotyped, single-
cycle HIV-1 vector devoid of all accessory genes, wherein the viral
genes are under the transcriptional regulation of the cytomega-
lovirus promoter, they concluded that the cPPT-CTS of the DNA
flap was most critical for nuclear import of viral DNA in
peripheral blood lymphocytes, monocyte-derived dendritic cells
(MDDCs) and macrophages [30]. They also reported that the
Vpr-deleted mutant HIV-1 vector was similar to its Vpr-
expressing counterpart in transduction of the three primary cell
types that were tested and did not influence the nuclear import
process. However, it is important to note that using a promoter-
modified HIV-1 vector cannot fully reflect LTR promoter-driven
viral replication and gene expression in infected cells.
To better understand the effects of Vpr on HIV-1 infection
under highly permissive and less permissive cell type conditions,
we examined the role of Vpr in activated peripheral blood
mononucleocytes (PBMCs), CD4
+ T-cells, and MDDCs in the
context of single-cycle and replication-competent HIV-1 infec-
tions. Our results indicate that Vpr significantly enhances single-
cycle HIV-1 infection in PBMCs, CD4
+ T-cells and MDDCs. In
contrast, Vpr significantly enhances replication of spreading HIV-
1 infection in MDDCs, but not in PBMCs. Our data suggest
distinct differences in the role of Vpr in single-cycle and
replication-competent HIV-1 infection that are dependent on
the permissiveness and cell cycle status of the target cell.
Results
Characterization of Vpr
+ and Vpr
2 Single-cycle, VSV-G-
pseudotyped HIV-1 Stocks
To evaluate HIV-1 production and infectivity in the presence
or absence of Vpr, we conducted a careful characterization and
titration of the Vpr
+ and Vpr
2 virus stocks. The luciferase
reporter HIV-1 proviral vectors NL-Luc-E
2R
+ (Vpr
+) and the
NL-Luc-E
2R
2 (Vpr
2) were used for single-cycle virus produc-
tion, which contain an intact Vpr open-reading-frame (ORF) or
a frame-shift mutant of Vpr, respectively [21]. Prior to virus
production, we confirmed that the frame-shift mutation in the
Vpr ORF did not aberrantly affect the expression of the
luciferase reporter gene by transfecting HEK293T cells with the
pNL-Luc-E
2R
+ and pNL-Luc-E
2R
2 proviral plasmids and
measuring luciferase reporter expression. Our results indicated
that LTR-driven luciferase reporter gene expression from the vpr-
deleted proviral plasmid was similar to its vpr-expressing
counterpart (Fig. 1A). The proviral plasmids were then used to
generate single-cycle HIV-1 pseudotyped with the VSV-G
envelope from HEK293T cells. Similar levels of p24 capsid
protein were detected in the two viral stocks (Fig. 1B and
Table 1), which indicated that the lack of Vpr did not
significantly affect virus production. Immunoblotting of lysed,
HIV-1 Vpr
+ and Vpr
2 viral particles confirmed that Vpr was
only incorporated in the HIV-1 Vpr
+ due to an intact ORF
contained within the NL-Luc-E
2R
+ vector (Fig. 1B).
To assess the infectivity of the single-cycle HIV-1 stocks, a
limiting dilution infectivity assay was conducted on GHOST/R5
indicator cells and an infectious titer and relative infectivity was
calculated for each virus stock. GHOST/R5 cells are human
osteosarcoma cells that express CD4 and CCR5 and contain a
GFP gene under the control of the HIV-2 LTR promoter, which
is expressed during HIV-1 infection via Tat transactivation acting
as an indicator of infection [34,35,36]. Our results confirmed that
HIV-1 Vpr
+ and HIV-1 Vpr
2 were equally infectious in the
GHOST/R5 indicator cell line (Table 1). Similar luciferase
activities were obtained when HEK293T cells were infected with
these single-cycle viruses (data not shown). Thus, Vpr expression
does not significantly affect single-cycle HIV-1 production and
virion infectivity.
Vpr Enhances Single-cycle HIV-1 Infection of Activated
PBMCs, Primary CD4
+ T Cells and MDDCs
To examine the role of Vpr in HIV-1 infection, we compared
the infection of the two viruses on PHA-activated PBMCs,
primary CD4
+ T-cells, and MDDCs. Cells were separately
infected with Vpr
+ and Vpr
2 single-cycle HIV-1 at an MOI of
1 and the level of infection was monitored over a 7-day period by
measuring luciferase reporter expression. The infection of HIV-1
Vpr
+ was robust in the highly permissive, activated PBMCs and
CD4
+ T-cells and the peak of luciferase expression was reached at
3 days post-infection (dpi) and declined sharply at 5 dpi (Fig. 2A
and 2B). Such a sharp decline in luciferase expression in Vpr
+
single cycle infected CD4
+ primary T-cells has been previously
reported and is attributed to Vpr induced inhibition of cell growth
and/or cell death [37]. In contrast, HIV-1 Vpr
2 failed to establish
Figure 1. Characterization of Vpr
+ and Vpr
2 single-cycle, VSV-
G-pseudotyped HIV-1 stocks produced from HEK293T cells. (A)
Quantification of luciferase (Luc) expression from the pNL-Luc-E
2R
+
(HIV-1 Vpr
+) and pNL-Luc-E
2R
2 (HIV-1 Vpr
2) proviral DNA constructs in
HEK293T cells. Luciferase activity was determined 48 h following
plasmid transfection and normalized to protein content. Error bars
represent the standard deviation of the mean of three independent
experiments. (B) The VSV-G pseudotyped, HIV-1 Vpr
+ and HIV-1 Vpr
2
stocks generated from pNL-Luc-E
2R
+ and pNL-Luc-E
2R
2 were analyzed
by immunoblotting for the incorporation of Vpr into virion particles.
doi:10.1371/journal.pone.0035385.g001
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amount of luciferase expressed from the infected cells at 3 and
5 dpi. At 3 dpi, the level of HIV-1 Vpr
+ infection was 5-7-fold
higher (P,0.05) than that of HIV-1 Vpr
2 in PBMCs and CD4
+
T-cells, respectively (Fig. 2A and 2B). In the less permissive, non-
dividing MDDCs, infection of HIV-1 Vpr
+ was 28-fold higher
(P,0.05) than that of HIV-1 Vpr
2 at 7 dpi (Fig. 2C). Further-
more, luciferase expression from HIV-1 Vpr
+ infected MDDCs
steadily increased over the 7-day period (Fig. 2C). However, the
overall infection of HIV-1 Vpr
+ in PBMCs was approximately 8-
fold higher (P,0.05) than that in MDDCs (Fig. 2A and 2C). These
results suggested that Vpr is required for efficient single-round
HIV-1 infection of both permissive and less-permissive target cell
types of HIV-1.
Vpr-mediated Enhancement of Single-cycle HIV-1
Infection is Independent of VSV-G and Ampho Envelopes
used for Virus Pseudotyping
Next, we assessed whether a transformed T-cell line, such as
CD4
+ HuT/CCR5 cells [34], would still require the presence of
Vpr to establish a robust single-cycle HIV-1 infection as observed
with PBMCs and primary CD4
+ T-cells. Accordingly, HuT/
CCR5 cells were infected with VSV-G-pseudotyped Vpr
+ and
Vpr
2 single-cycle HIV-1 at an MOI of 1, and infection was
monitored by luciferase expression over a 7-day period. Similar to
what was observed with CD4
+ primary T-cells, the infection of
HuT/CCR5 cells with Vpr
+ HIV-1 was 15-fold higher (P,0.05)
compared with Vpr
2 HIV-1 infection (Fig. 3A). These results were
unexpected as a previous study has shown that Vpr is not required
for single-cycle HIV-1 infection in dividing cells [21].
To rule out the possibility that Vpr-mediated enhancement of
HIV-1 infection was dependent on the type of envelope used for
virus entry, NL-Luc-E
2 single cycle virus stocks were generated
using the same HIV-1 vectors but pseudotyped with the MLV
amphotrophic envelope (Ampho), which has been used by
previous studies of Vpr function [21,37]. The HIV-1 Vpr
+/
Ampho and HIV-1 Vpr
2/Ampho viral stocks were evaluated for
the incorporation of Vpr in the virion by immunoblotting
(Fig. 3B). HIV-1 p24 capsid concentration, infectious titer, and
specific infectivity were examined (Table 1). Both virus stocks
contained similar p24 levels and infected GHOST/R5 indicator
cells in a similar manner. We then infected HuT/CCR5 cells
with HIV-1 Vpr
+/Ampho and HIV-1 Vpr
2/Ampho stocks at an
MOI of 1 and assessed luciferase expression at 3 dpi, since peak
infection was reached at this time-point with the VSV-G
pseudotyped virus infection (Fig. 3A). Our results indicated that
the infection of HIV-1 Vpr
+/Ampho was approximately 10-fold
higher (P=0.00004) than the HIV-1 Vpr
2/Ampho (Fig. 3C).
These data suggest that single-cycle HIV-1 infection is enhanced
significantly in the presence of Vpr independent of the type of
heterologous virus envelope used for endocytosis-mediated virus
entry.
Quantification of the Levels of HIV-1 viral DNA Species
Generated in Target Cells Following Single-cycle
Infection
To identify at which step during the virus life cycle Vpr played a
significant role to enhance single-cycle HIV-1 infection in both
highly permissive and less permissive cell types, we performed real-
time PCR analysis and quantified late reverse transcription (late
RT) products, 2-LTR circles, and integrated copies of provirus
following infection of the two cell types. Late RT products
represent the full reverse transcribed viral DNA. Although 2-LTR
circles produced from fully reverse-transcribed HIV-1 DNA are
abortive products, they can be used as a surrogate marker for
nuclear import of the viral DNA [38]. The amount of integrated
proviral DNA in infected cells was quantified using Alu-gag-based
real-time PCR [38]. Since we observed a distinct deficit in Vpr
2
single-cycle HIV-1 infection in the HuT/CCR5 cell line (Fig. 3A),
which was similar to what was observed in CD4
+ primary T-cells
(Fig. 2B), we performed quantitative PCR analysis in infected
HuT/CCR5 cells and MDDCs.
Our results indicate that the quantities of late RT products,
which are generated upon completion of the reverse transcription
process, were similar in HIV-1 Vpr
+ and Vpr
2 infected HuT/
CCR5 cells and declined with similar kinetics over a 48-h time
period beginning at 24 h post-infection (Fig. 4A). However, a
modest, but not statistically significant increase (P=0.09) in the
quantities of 2-LTR circles was observed at 24 h post-infection in
HIV-1 Vpr
+ infected HuT/CCR5 cells (Fig. 4B). These data
suggest that nuclear import of HIV-1 DNA might be to some
extent more efficient in these actively dividing cells in the presence
of Vpr. However, the number of integrated proviral DNA copies
was similar in HIV-1 Vpr
+ and Vpr
2 infected HuT/CCR5 cells at
24 and 48 h post-infection with a slight increase at 72 h in the
presence of Vpr (Fig. 4C).
Table 1. Titration of infectivity of single-cycle and replication-competent HIV-1 stocks.
HIV-1 stocks p24 concentration (ng/ml) Infectious titer (IU/ml) Relative infectivity (IU/ng of p24)
Vpr
+/VSV-G
a 254 8.17610
6 3.29610
4
Vpr
2/VSV-G
a 173 6.34610
6 3.66610
4
Vpr
2/VSV-G (Vpr complemented)
a 114 8.66610
6 7.59610
4
Vpr
+/Ampho
b 305 7.69610
5 2.52610
3
Vpr
2/Ampho
b 309 6.77610
5 2.19610
3
NLAD8 WT
c 720 2.26610
7 3.14610
4
NLAD8 DVpr
c 680 1.91610
7 2.81610
4
aSingle-cycle, VSV-G-pseudotyped luciferase reporter HIV-1 Vpr
+, HIV-1 Vpr
2, and Vpr complemented HIV-1 Vpr
2 stocks. The data represent average results of
duplicated samples from two independent experiments.
bSingle-cycle, MLV amphotrophic (Ampho) envelope-pseudotyped luciferase reporter HIV-1 Vpr
+ and HIV-1 Vpr
2 virus stocks.
cReplication-competent HIV-1NLAD8(WT) and HIV-1NLAD8(DVpr) stocks. All viral stocks were prepared from HEK293T cells and analyzed for p24 concentration by ELISA. The
infectivity of each virus stock was evaluated on HIV-1 indicator GHOST/R5 cells by a limiting dilution assay [35]. The relative infectivity of each virus stock is presented as
the number of infectious units (IU) per 1 ng of p24.
doi:10.1371/journal.pone.0035385.t001
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late RT products was observed in HIV-1 Vpr
+ infected cells over
a 72-h time period following infection compared with the HIV-1
Vpr
2 infected cells where a constant, relatively low level of late
RT products were maintained (Fig. 4D). While 2-LTR circles
and the number of integrated proviral DNA were only above the
detection limit (10 copies) at 72 h post-infection, a result of
slower infection kinetics and relatively lower level of infection in
Figure 2. Vpr enhances single-cycle HIV-1 infection of activat-
ed PBMCs, primary CD4
+ T cells, and MDDCs. (A) PHA-activated
peripheral blood mononucleocytes (PBMCs), (B) PHA-activated CD4
+ T
cells, and (C) Monocyte-derived dendritic cells (MDDCs) were infected at
an MOI of 1.0 with single-cycle HIV-1 Vpr
+/VSV-G and HIV-1 Vpr
2/VSV-G
to test the role of Vpr in HIV-1 infection. Luciferase expression from the
integrated provirus in the infected cells was assessed at the indicated
time and normalized to protein content (10 mg/sample). The data
shown represents one of three independent experiments carried out for
each cell type from three different donors. Error bars represent the
standard deviation of the mean of triplicate samples. Statistically
significant differences are indicated by the asterisks (P,0.05).
doi:10.1371/journal.pone.0035385.g002
Figure 3. Vpr-mediated enhancement of single-cycle HIV-1
infection is independent of VSV-G and Ampho envelopes used
for virus pseudotyping. (A) HuT/CCR5 cells were infected at an MOI
of 1.0 with single-cycle HIV-1 Vpr
+/VSV-G and HIV-1 Vpr
2/VSV-G.
Luciferase expression from the integrated provirus in the infected cells
was assessed at the indicated time and normalized to protein content
(10 mg/sample). The data shown represents one of three independent
experiments, and error bars represent standard deviation of the mean
of triplicate samples. (B) The MLV amphotrophic (Ampho) envelope
pseudotyped, HIV-1 Vpr
+ and HIV-1 Vpr
2 stocks generated from pNL-
Luc-E
2R
+ and pNL-Luc-E
2R
2 proviral constructs were analyzed by
immunoblotting for the presence of Vpr. (C) HuT/CCR5 cells were
infected at an MOI of 1.0 with HIV-1 Vpr
+/Ampho and HIV-1 Vpr
2/
Ampho. Luciferase expression from the integrated provirus in the
infected cells was assessed 3 days post infection and normalized to
protein content. Error bars represent standard deviation of the mean of
triplicate samples. Statistically significant differences are indicated by
the asterisks (P,0.05) and the P value.
doi:10.1371/journal.pone.0035385.g003
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and integrated viral species were higher in the presence of Vpr
(Fig. 4E and 4F). These results suggest that Vpr plays a more
important role in enhancing the reverse transcription and nuclear
import processes of a single-round HIV-1 infection in MDDCs
relative to HuT/CCR5 cells.
Vpr Significantly Enhances HIV-1 gag mRNA Levels in
HuT/CCR5 Cells and MDDCs
Vpr is a known transactivator of LTR-driven viral gene
expression [9,12], and thus, we questioned whether the increase
in luciferase reporter gene expression from the integrated Vpr
+
single cycle provirus compared with the Vpr
2 provirus could
Figure 4. Comparison of the viral DNA profiles in single-cycle HIV-1 Vpr
+/VSV-G and HIV-1 Vpr
2/VSV-G infected cells. Cellular DNA
was isolated from single cycle HIV-1 Vpr
+/VSV-G and HIV-1 Vpr
2/VSV-G infected HuT/CCR5 cells (A-C) and MDDCs (D-F) at 24, 48 and 72 h post-
infection and subjected to real-time quantitative PCR analysis using Taqman-based primer/probe sets specific to quantify the levels of late-reverse
transcription (Late-RT) products, 2-LTR circles, and integrated proviral copies. The amounts of genomic DNA used for the PCR are indicated in each
panel. Real-time PCR amplification of the glyceraldehyde-3-phosphate dehydrogenase gene was performed for each sample to normalize for the
amount of input DNA in each of the amplification reactions. Error bars represent standard error of the mean of duplicate samples. UD; undetectable
under current experimental conditions. Statistically significant differences are indicated by P values. The MDDC data shown represents one of three
independent experiments using cells from three different donors.
doi:10.1371/journal.pone.0035385.g004
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To this end total cellular RNA was extracted from HIV-1 Vpr
+
and Vpr
2 infected HuT/CCR5 cells and MDDCs, and
subjected to real-time PCR to quantify the levels of HIV-1
gag mRNA produced from the infected cells. We quantified gag
mRNA levels at 3 days post-infection in HuT/CCR5 cells and
4 days post-infection in MDDCs. These time points were
chosen based on the reasoning that peak infection with single
cycle HIV-1 occurred on or before these time points in the two
cell types (Fig. 2B and 2C). We observed a significant increase
(7-fold, P ,0.05) in the number of gag mRNA copies in HIV-1
Vpr
+ infected HuT/CCR5 cells and in MDDCs compared with
the HIV-1 Vpr
2 infected cells (Fig. 5A and 5B, respectively),
which suggests that Vpr-mediated LTR transactivation is the
likely cause for the enhancement in luciferase reporter
expression from the infected in HuT/CCR5 cells and MDDCs.
Knockdown of DCAF1 in HuT/CCR5 Cells does not Affect
Single-cycle HIV-1 Infection
To test whether the Vpr-mediated enhancement of single-cycle
HIV-1 infection involved the DDB1/DCAF1/Cul4A complex
and proteasomal degradation, DCAF1 was transiently knocked
down in HuT/CCR5 cells using lentiviral vectors expressing
shRNA-specific to DCAF1 and a scrambled shRNA vector was
used as a control (Fig. 6A). The partial reduction in DCAF1
levels did not affect the infection of the HIV-1 Vpr
+ and HIV-1
Vpr
+ (Fig. 6A and 6B), suggesting that the Vpr-mediated
enhancement of infection in HuT/CCR5 cells did not involve
the recruitment of the DCAF1/DDB1/Cul4A complex and
proteasomal degradation. Our result is consistent with a recent
report by Pertel and colleagues, wherein they demonstrated that
Vpr
+ single-cycle HIV-1 infection of MDDCs was independent
of DCAF1 [39].
Vpr Complementation does not Affect Vpr-defective HIV-
1 infection of MDDCs
Since high levels of Vpr can be incorporated into HIV-1 virions
[5], we questioned whether the enhancement of HIV-1 infection
of MDDCs resulted from incorporated Vpr into virions or newly
synthesized Vpr in infected cells. To address this question, single-
cycle HIV-1 with Vpr complementation was used in infection
assays. High levels of Vpr were efficiently complemented into Vpr-
negative single-cycle HIV-VSV-G as confirmed by immunoblot-
ting (Fig. 7A). However, Vpr complementation did not affect
single-cycle HIV-1 infection of MDDCs (Fig. 7B), suggesting that
newly synthesized Vpr protein in infected MDDCs is required for
efficient HIV-1 infection.
Vpr Significantly Enhances Replication-competent HIV-
1NLAD8 Infection in MDDCs
We next assessed whether Vpr of a replication-competent HIV-
1 can enhance viral infection of PBMCs and MDDCs during
multiple rounds of infection. Given that MDDCs are more
susceptible to R5-tropic HIV-1 than to X4-tropic HIV-1 [40,41],
the R5-tropic strain HIV-1NLAD8 was used to compare the role of
Vpr in HIV-1 infection. Individual virus stocks were evaluated for
the incorporation of Vpr in the virion (Fig. 8A), p24 capsid
concentration, infectious titer, and relative infectivity (Table 1).
Comparable levels of p24 capsid protein were detected in the
HIV-1NLAD8 WT and DVpr stocks and a limiting dilution
infectivity assay on GHOST/R5 indicator cells confirmed that
the DVpr virus was comparable in its infectivity to its WT
counterpart (Table 1).
To assess the contribution of Vpr during multiple rounds of
HIV-1 infection, PHA-stimulated PBMCs and MDDCs were
infected with 5 ng and 20 ng of p24 from each virus type,
respectively, and the level of infection was monitored over a 7- or
10-day period by quantifying the p24 production in the culture
Figure 5. Vpr significantly enhances HIV-1 gag mRNA levels in HuT/CCR5 cells and MDDCs. Total cellular RNA was isolated from single
cycle HIV-1 Vpr
+/VSV-G and HIV-1 Vpr
2/VSV-G infected HuT/CCR5 cells (A) and MDDCs (B) at 3 and 4 days post-infection, respectively, and subjected
to RT-PCR to quantify the levels of HIV-1 gag mRNA copies in each cell type. The amplification of the glyceraldehyde-3-phosphate dehydrogenase
gene was also performed for each sample to normalize for the amount of input cDNA in each of the amplification reactions. The data is represented
as the fold change in the number of gag mRNA copies relative to the HIV-1 Vpr
2/VSV-G infected sample in each cell type. Statistically significant
differences are indicated by the asterisks (P,0.05). The MDDC data shown represents one of two independent experiments using cells from two
different donors.
doi:10.1371/journal.pone.0035385.g005
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replicated at a slightly lower rate compared with the WT virus at 3
and 5 dpi (P,0.05), with both viruses displaying robust infections
in activated PBMCs at 10 dpi (Fig. 8B). However, the disparity
between the WT and DVpr virus was more far-reaching in
MDDCs, where a 3-fold increase (P, 0.05) in infection was
observed with the WT virus compared with the DVpr virus at
5 dpi (Fig. 8C), which is usually the peak of WT HIV-1 infection
in MDDCs [42,43]. These results suggest that during a spreading
infection, the action of Vpr in enhancing HIV-1 replication in
MDDCs compared with PBMCs is more readily observed.
Comparison of the Viral DNA Profiles in HIV-1NLAD8 and
HIV-1NLAD8DVpr Infected Cells
To better understand the mechanisms by which Vpr enhances
spreading infection, we performed quantitative PCR analysis on
DNA isolated from either WT or DVpr HIV-1 infected PBMCs
and MDDCs to determine the levels of late RT, 2-LTR circles and
integrated proviral copies generated in the infected cells over
multiple rounds of infection. Late RT products peaked at 3 dpi in
both PBMCs and MDDCs with a modest increase in the presence
of Vpr (P,0.05) (Fig. 9A and 9D). In both cell types, the levels of
2-LTR circles were higher in the presence of Vpr at 3 dpi (Fig. 9B
and 9E). In addition, we measured integrated proviral copies at
3 dpi in PBMCs and observed a 1.8-fold increase (P=0.04) in the
number of integrated copies in WT virus-infected cells compared
with the DVpr virus infected cells (Fig. 9C). In a similar manner,
the number of integrated proviral copies was higher in the
presence of Vpr expression in MDDCs (2.5-fold, P=0.03) (Fig. 9F).
As expected, the number of integrated proviral copies in MDDCs
was 15-20-fold lower than in activated PBMCs (Fig. 9C and 9F).
Collectively, our data indicate that Vpr increases nuclear import
and integration of HIV-1 DNA in PBMCs and MDDCs, although
ensuing virus production is significantly enhanced only in the less
permissive MDDCs.
Discussion
In the current study we compared the role of the HIV-1
accessory protein, Vpr, during single-cycle and replication-
competent HIV-1 infection of PBMCs, CD4
+ T-cells and
MDDCs, cell types that are distinct with respect to their cell
cycle status and susceptibility to HIV-1 infection. Single-cycle
HIV-1 infection enables the study of viral and cellular factors
affecting the HIV-1 virus life cycle to the point of viral DNA
integration with the ensuing production of viral particles that lack
Figure 6. DCAF1 knockdown in HuT/CCR5 cells does not affect
single-cycle HIV-1 infection. HuT/CCR5 cells were transduced with
concentrated lentivirus expressing either shRNA targeting DCAF1 or a
scrambled shRNA (control). Three days following transduction a fraction
of cells were analyzed by immunoblotting to confirm DCAF1
knockdown (A), and cells each were infected at an MOI of 0.5 with
either HIV-1 Vpr
+/VSV-G or HIV-1 Vpr
2/VSV-G to test whether DCAF1
was involved in the Vpr-mediated enhancement of HIV-1 infection (B).
Luciferase expression in the infected cells was assessed at 3 days post
infection.
doi:10.1371/journal.pone.0035385.g006
Figure 7. Vpr complementation does not affect Vpr-defective
single-cycle HIV-1 infection of MDDCs. (A) Vpr incorporation in
VSV-G-pseudotyped, single-cycle HIV-Vpr+ and Vpr-complemented HIV-
Vpr-. Virion pellets were analyzed by immunoblotting with anti-Vpr and
anti-p24, respectively. (B) Vpr complementation does not affect single-
cycle HIV-Vpr- infection of MDDCs. Infected cells were lysed at indicated
times post infection for the detection of HIV-1 infection by measuring
luciferase activity and normalized to protein content (20 mg/sample).
cps, counts per second. The data shown represents one of three
independent experiments carried out with three individual donors.
doi:10.1371/journal.pone.0035385.g007
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infection within the target cells. During single-cycle HIV-1
infection of PHA-activated primary PBMCs and CD4
+ T-cells,
we observed that Vpr significantly enhanced viral infection, which
is in contrast to previously published results by Connor et al [21].
This initial study employed the same proviral constructs used in
our study, but used the MLV amphotrophic envelope for virus
pseudotyping. They showed that in the presence of polybrene, a
cationic polymer that is used to enhance retroviral infection
in vitro, the HIV-1 Vpr
2 virus was able to infect activated PBMCs
similar to the HIV-1 Vpr
+ virus as determined by luciferase
reporter expression. In contrast, we did not use polybrene and
carefully titrated viral stocks in our infections. The discrepancy in
results might be due to different experimental approaches
including viral titration.
Given that PBMCs constitute a mixed population of mononu-
clear cells such as CD4
+ and CD8
+ T-cells, B-cells, monocytes,
and dendritic cells etc., we isolated primary CD4
+ T-cells from
PBMCs and infected with single-cycle, Vpr
+ and Vpr
2 HIV-1.
The results obtained from the primary CD4
+ T-cells confirmed
our findings in PBMCs and provided corroborative evidence that
Vpr enhances single-cycle HIV-1 infection (Fig. 2B). Furthermore,
pseudotyping of the single-cycle Vpr
2 HIV-1 vector with an MLV
amphotropic envelope displayed a similar defect in infection
compared with the HIV-1 Vpr
+/Ampho virus. Our results
indicated that the lack of infectivity displayed by the single cycle,
Vpr
2 HIV-1 was due to a post-entry event independent of the
type of heterologous virus envelope used for enodocytosis-
mediated virus entry into the target cell.
Based on our quantitative PCR analysis of the viral DNA
profiles in infected HuT/CCR5 cells, it appears that Vpr does not
significantly affect the levels of late RT products, 2-LTR circles,
and integration of viral DNA. Consistent with Vpr’s well-known
ability to transactivate LTR-driven viral gene expression
[9,10,25], we observed that gag mRNA levels was significantly
increased in HIV-1 Vpr
+ infected HuT/CCR5 cells compared to
the HIV-1 Vpr
2 infected cells, which appears to be the main
contributing factor for the enhanced infection of single cycle HIV-
1 expressing Vpr. Furthermore, our data indicated that DCAF1 is
not required for Vpr-enhanced HIV-1 infection in HuT/CCR5
cells, which is consistent with a recent report demonstrating that
single-cycle HIV-1 infection of MDDCs is independent of DCAF1
[39].
DCs share a common myeloid lineage as macrophages, which
are also a target cell type of HIV-1 in initial viral infection, and
have been implicated as possible viral reservoirs harboring latent
HIV-1 virus [44]. Similar to DCs, macrophages are non-dividing
cells, but are more permissive to HIV-1 provided Vpr is expressed
from the HIV-1 genome [21,22,25]. Macrophages were the initial
myeloid cell type to be used in studies, which indicated that Vpr
was required for efficient nuclear import of HIV-1 DNA in non-
dividing cell types [23,25]. Thus, it is not surprising that DCs share
the same requirement of Vpr for efficient HIV-1 infection.
Interestingly, we found that in HIV-1 Vpr
+ infected MDDCs, the
quantities of late RT products steadily increased over the assessed
time compared to HIV-1 Vpr
2 infected cells (Fig. 4D). Given the
slow infection kinetics in DCs, it is conceivable that the reverse
transcription process occurs more efficiently in the presence of
Vpr. Furthermore, based on the low level of infection that was
achieved in MDDCs the number of 2-LTR circles and integrated
proviral copies only exceeded the detection limit at 72 h post-
infection with results indicating an increase in both viral DNA
products in HIV-1 Vpr
+ infected cells. Similar results have been
reported previously in macrophages, which lead to the conclusion
Figure 8. Vpr significantly enhances replication-competent
HIV-1NLAD8 infection in MDDCs. (A) The HIV-1NLAD8 and HIV-
1NLAD8DVpr virus stocks produced from HEK293T cells were analyzed by
immunoblotting for the presence of Vpr. (B) PHA-activated PBMCs and
(C) MDDCs were infected with 5 ng and 20 ng of p24, respectively, from
HIV-1NLAD8 and HIV-1NLAD8DVpr virus and levels of p24 capsid released
into the media during virus replication were assayed over a period of
10 days and 7 days post infection for PBMCs and MDDCs, respectively.
The data shown represents one of three independent experiments
carried out with three individual donors, and error bars represent
standard deviation of triplicate infections. Statistically significant
differences are indicated by the asterisks (P,0.05).
doi:10.1371/journal.pone.0035385.g008
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cells [23,25]. However, we also observed an enhancement in gag
mRNA levels in HIV-1 Vpr
+ infected MDDCs compared with the
HIV-1 Vpr
2 infected cells, thus indicating that Vpr is capable of
facilitating LTR-driven viral gene expression to enhance single
cycle HIV-1 infection in DCs. Moreover, Vpr complementation
into HIV-1 virions did not affect single-cycle HIV-1 infection of
MDDCs, suggesting that Vpr-mediated enhancement of HIV-1
infection in MDDCs is exerted by the Vpr protein synthesized
upon establishing infection, but not due to the Vpr protein
associated with viral particles. Our results are in agreement with a
previous study of Vpr in promoting HIV-1 infection of primary
monocytes and macrophages [21].
Further confirmation for the role of Vpr in HIV-1 infection in
DCs was obtained using replication-competent HIV-1
NLAD8(WT) and NLAD8(DVpr). However, Vpr did not seem
to significantly enhance virus replication in activated PBMCs,
which are more susceptible to spreading infection compared with
MDDCs. This is consistent with an earlier study by Rey et al.,
wherein they reported an impairment of nuclear import of viral
DNA in stimulated PBMCs in the absence of Vpr, which resulted
in a subtle effect in virus production [45].
Figure 9. Comparison of the viral DNA profiles in HIV-1NLAD8 and HIV-1NLAD8DVpr infected cells. Quantitative PCR analysis was performed
to determine levels of late reverse transcription (Late-RT) products, 2-LTR circles, and integrated proviral copies over a period of 7 days following
infection of activated PBMCs (A-C) and MDDCs (D-F) following infection with HIV-1NLAD8 and HIV-1NLAD8DVpr. Real-time PCR amplification of
the glyceraldehyde-3-phosphate dehydrogenase gene was performed for each sample to normalize for the amount of input DNA in each of the
amplification reactions. Error bars represent standard error of the mean of duplicate samples. Statistically significant differences are indicated by the
asterisks (P,0.05) and P values. The data shown represents one of three independent experiments carried out for each cell type from three different
donors.
doi:10.1371/journal.pone.0035385.g009
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1 infection, which has been attributed to the presence of cellular
restriction factors (reviewed in [46,47]). The recent discovery of
SAMHD1 as a cellular restriction factor of HIV-1 in myeloid
cells provides evidence for such a notion [48,49]. SAMHD1-
mediated restriction of HIV-1 can be counteracted by the
SIVmac/HIV-2 Vpx protein, which is absent in HIV-1. SIV/
HIV-2 Vpx, but not HIV-1 Vpr, efficiently enhances SIV/HIV-
1-derived lentiviral vector transduction of human monocytes,
macrophages, or MDDCs (reviewed in [46]). HIV-1 and
SIVmac Vpr cannot bind and degrade SAMHD1 [49],
suggesting that Vpr is not able to counteract SAMHD1-
mediated HIV-1 restriction in myeloid cells. Similar to several
CD4
+ T-cell lines [48], Hut/CCR5 cells do not express
detectable SAMHD1 protein (data not shown). Despite the
structural similarity between Vpx and Vpr from SIVmac, only
Vpx, but not Vpr, can efficiently promote HIV-1 infection of
human macrophages and the amino-terminal domain of Vpx is
important for the enhancement of HIV-1 infection [50]. It
remains to be determined whether the amino-terminal domain
of HIV-1 Vpr is critical for its enhancement of viral infection.
Moreover, APOBEC3A has been recently reported as a
inhibitor of HIV-1 infection in myeloid cells [51]. Therefore,
HIV-1 restriction in myeloid cell types may attribute to multiple
host factors, which remains to be confirmed.
Our results indicate that Vpr enhances single-cycle and
replication-competent HIV-1 infection in MDDCs. It remains
unclear whether the enhancement in MDDCs is due to the
counteraction of a cellular restriction factor by Vpr, although
analysis of the different HIV-1 DNA in infected cells did not
clearly indicate a restriction point. Furthermore, numerous
cellular interacting partners of Vpr have been identified over
the years, but none have been found to be restrictive of HIV-1
infection (reviewed in [7,52]). It is possible that the Vpr-
mediated enhancement of HIV-1 infection in MDDCs is not via
the counteraction of a cellular restriction factor by Vpr, but
merely by a synergistic effect on the different stages of the virus
life cycle beginning with reverse transcription and ending with
the regulation of viral genes. Further study of the mechanisms
by which Vpr enhances HIV-1 infection will provide new
insights into Vpr function in viral pathogenesis.
Materials and Methods
HIV-1 Stocks
Single-cycle, luciferase reporter HIV-1 stocks were generated by
calcium phosphate-based transfection of HEK293T cells with the
pNL-Luc-E
2R
+ proviral DNA vector, which contains an intact vpr
gene or a frame-shift mutant of the vpr gene (pNL-Luc-E
2R
2),
together with a construct expressing vesicular stomatitis virus
glycoprotein (pVSV-G) [35] or murine leukemia virus (MLV)
amphotrophic envelope glycoprotein (Ampho). Both proviral
DNA constructs were kindly provided by Dr. Nathaniel Landau
(New York University). Replication-competent HIV-1NLAD8 and
HIV-1NLAD8DVpr stocks were generated in HEK293T cells by
calcium phosphate transfection of pNLAD8 and pNLAD8(DVpr),
respectively [33] as described [43]. The p24 level in all virus stocks
was determined using a p24 enzyme-linked immunosorbent assay
(ELISA) kit (SAIC-Frederick) and the infectivity of each virus
stock, represented as the infectious unit titer, was determined by
limiting dilution on HIV-1 indicator GHOST/R5 cells as
previously described [35].
Immunoblotting
To confirm incorporation of Vpr in the virion particle in each
virus stock, equivalent volumes of virus-containing media (1 ml)
was ultracentrifuged at 35,000 rpm for 2 h at 4uC in a SW55
rotor. The virus pellet was lysed in 16cell lysis buffer (Cell
Signaling Technology) and subjected to immunoblotting using a
polyclonal rabbit anti-Vpr antibody (the AIDS Research and
Reference Reagent Program, NIH). Immunoblotting for p24
capsid protein was also conducted using a monoclonal mouse anti-
p24 antibody as described [43] (clone #24-2, the AIDS Research
and Reference Reagent Program, NIH).
Cell Culture
PBMCs and monocytes were isolated from buffy coat from
healthy blood donors by histopaque and percoll gradient
centrifugation as previously described [40]. MDDCs were
generated by treatment of monocytes with interleukin-4 (50 ng/
ml) and granulocyte/macrophage-colony stimulating factor
(50 ng/ml) for 5 days in culture. Primary CD4
+ T cells were
isolated from PBMCs using magnetic beads coated with CD4
antibodies (BD Biosciences). HEK293T, GHOST/R5, and Hut/
CCR5 cell lines [34,53] were kind gifts from Vineet KewalRamani
(National Cancer Institute) and were maintained in specific media
as previously described [34].
HIV-1 Infection
For infections with single-cycle luciferase reporter HIV-1
viruses, MDDCs (2.5610
5) were infected at a multiplicity of
infection (MOI) of 1 for 2 h at 37uC. Thereafter, the cells were
washed twice in DPBS and cultured over a 7-day period.
Activation of PBMCs and CD4
+ T-cells were carried out with
phytohemagglutinin (PHA; 5 mg/ml) and IL-2 (20 U/ml) for 24 h
prior to infection with single cycle luciferase-reporter HIV-1 at an
MOI of 1. At day 1, 3, 5 and 7 post-infection, cells were harvested,
lysed in 16reporter lysis buffer (Promega), and luciferase activity
was detected using a commercially available kit (Promega).
Infection of MDDCs with replication-competent HIV-1NLAD8
virus was conducted in a similar manner to the single cycle virus
infections with 2.5610
5 PHA-activated PBMCs or MDDCs
infected with 5 ng and 20 ng of p24, respectively. Gag p24
released into the culture supernatant during the infection period
was assessed by ELISA as previously described [40].
Quantitative PCR Analysis
Levels of late reverse transcription products, 2-LTR circles and
integrated copies of provirus in infected MDDCs and activated
PBMCs were quantified by Taqman-based real-time quantitative
PCR analysis using primer and probe sets and protocols previously
described [38]. Specifically, 50 ng of genomic DNA from HIV-1
infected cells was used as input for the detection of late reverse
transcription products, and 150-250 ng for the detection of 2-LTR
circles and integrated proviral DNA. All virus stocks were treated
with DNaseI (40 U/ml; Ambion) prior to infections to avoid
plasmid DNA contamination. DNA from infected cells at various
time points was isolated using a DNeasy Blood and Tissue kit
(QIAgen).
RT-PCR Detection of gag mRNA
HuT/CCR5 cells and MDDCs (2.5610
5 cells) were infected
with either HIV-1 Vpr
+/VSV-G or HIV-1 Vpr
2/VSV-G (MOI
of 1) and harvested on day 3 (for HuT/CCR5 cells) and day 4 (for
MDDCs) post-infection. Total cellular RNA was isolated using an
RNeasy Mini kit (Invitrogen), and 250 ng of RNA was used as
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first-strand synthesis kit and oligo-dT primers (Invitrogen). Syber-
green-based real-time PCR analysis was performed using gag-
specific primers [38] to quantify the levels of HIV-1 gag mRNA
copies in each cell type. As standards for real-time PCR, serial
dilutions (10
6 to 10
2 copies) of the pNLAD8 plasmid were used for
the gag reaction. The amplification of glyceraldehyde-3-phosphate
dehydrogenase cDNA was also performed for each sample to
normalize for the amount of input cDNA in each of the
amplification reactions.
Lentivirus-mediated Knockdown of DCAF1 in Hut/CCR5
Cells
Lentivirus required for the shRNA-mediated knockdown of
DCAF1 was generated by calcium phosphate-based co-transfec-
tion of HEK293T cells with a DCAF-1-specific shRNA-expressing
lentiviral vector (pFG.12.3590) together with a packaging vector
(pCVM) and a VSV-G expressing vector (p-VSV-G). Two days
post-transfection, the media containing lentivirus were harvested,
spun down to remove cellular debris and concentrated 5-fold using
a 300,000 MW cut-off VIVASPIN 20 concentrator (Sartorius
Stedim). Thereafter, the concentrated lentivirus was incubated
with 2610
6 HuT/CCR5 cells together with 10 mg/ml polybrene
for 2 h at 37uC. Following incubation, the cells were washed twice
in 1X DPBS and re-plated in HuT/CCR5 cell media and cultured
for 3 days and the knockdown of DCAF1 protein level was
confirmed by immunoblotting using a rabbit polyclonal anti-
VPRBP (DCAF-1) antibody (Proteintech).
Vpr Complementation in Vpr-defective Single-cycle HIV-1
To generate single-cycle HIV-Luc/VSV-G complemented with
Vpr, HEK293T cells were cotransfected with a Vpr-expressing
construct (pcDNA-Vpr), pNL-Luc-E
–R
–, and pVSV-G to com-
plement Vpr into Vpr-negative viruses as previously described
[21]. The empty vector pcDNA was used as a negative control in
the transfection.
Statistical Analyses
Statistical analyses were performed using the Student’s t-test
with the Excel program. Statistical significance was defined as
P,0.05.
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